Jazz Q1 Earnings, Revenue Decline; Updates Outlook
Express News | Baird Maintains Outperform on Jazz Pharmaceuticals, Lowers Price Target to $155
RBC Capital Maintains Outperform on Jazz Pharmaceuticals, Lowers Price Target to $172
Jazz Pharmaceuticals Shares Are Trading Lower After the Company Reported Worse-than-expected Q1 Financial Results and Cut Its FY25 Adjusted EPS Guidance. Also, Piper Sandler and Morgan Stanley Lowered Their Respective Price Targets on the Stock.
Express News | Jazz Pharmaceuticals Shares Are Trading Lower After the Company Reported Worse-than-expected Q1 Financial Results and Cut Its FY25 Adjusted EPS Guidance. Also, Piper Sandler and Morgan Stanley Lowered Their Respective Price Targets on the Stock
Express News | Morgan Stanley Maintains Overweight on Jazz Pharmaceuticals, Lowers Price Target to $166
A Quick Look at Today's Ratings for Jazz Pharmaceuticals(JAZZ.US), With a Forecast Between $166 to $216
Express News | Needham Reiterates Buy on Jazz Pharmaceuticals, Maintains $200 Price Target
Jazz Pharmaceuticals Analyst Ratings
Analysts Conflicted on These Healthcare Names: Spyre Therapeutics (SYRE), Fresenius Medical Care (FMS) and Jazz Pharmaceuticals (JAZZ)
Jazz Pharmaceuticals | 10-Q: Quarterly report
Piper Sandler Sticks to Their Buy Rating for Jazz Pharmaceuticals (JAZZ)
Analysts Offer Insights on Healthcare Companies: Jazz Pharmaceuticals (JAZZ), Vera Therapeutics (VERA) and Dexcom (DXCM)
Earnings Call Summary | Jazz Pharmaceuticals(JAZZ.US) Q1 2025 Earnings Conference
Jazz Outlines $4.15B-$4.4B Revenue Target for 2025 Amid Growth in Neuroscience Portfolio and New Oncology Approvals
Express News | Jazz Pharmaceuticals PLC : Piper Sandler Cuts Target Price to $147 From $176
Optimistic Buy Rating for Jazz Pharmaceuticals Amid Growth Prospects and Strategic Positioning
Jazz Pharma Stock Falls After Lowered Full Year Guidance
Jazz Pharmaceuticals (JAZZ) Q1 Earnings and Revenues Lag Estimates
Trending Stocks Today | Klaviyo Climbs 6.01% Post-Market